Bill Vincent, Genezen Laboratories CEO

An In­di­ana CD­MO with big-name clients sets up plans for lentivi­ral pro­duc­tion site

An In­di­ana CD­MO fo­cused on gene ther­a­py is cash­ing in on the in­dus­try’s hot streak and un­veil­ing a mas­ter plan for a 75,000-square-foot lentivi­ral vec­tor pro­duc­tion site.

Genezen Lab­o­ra­to­ries broke ground on the con­struc­tion of a new plant out­side In­di­anapo­lis, IN. It will com­plete the first phase of con­struc­tion — good for 25,000 square feet — by au­tumn 2021, and the rest of the fa­cil­i­ty will go on­line by ear­ly 2022, the com­pa­ny said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.